Zydus Lifesciences' USA Office Clears USFDA Inspection With Nil Observations
Zydus Lifesciences Limited announced on Thursday that its US facility in New Jersey successfully completed a USFDA inspection with no observations. The inspection focused on the company's pharmacovigilance and post-marketing surveillance systems.
FPJ Web Desk
Updated: Saturday, September 26, 2026, 12:37 PM IST

Zydus Lifesciences |
Mumbai: Zydus Lifesciences Limited's USA office in New Jersey concluded a USFDA inspection of its pharmacovigilance and post-marketing surveillance system with 'nil observations', the company announced on 26 September 2026.
Inspection Details
The onsite inspection was conducted by the United States Food and Drug Administration (USFDA) from 22 September to 25 September 2026.
ALSO READ
Zydus Lifesciences Extends Sterling Biotech API Deal Deadline, Acquisition Closing Pushed To...
Company Background
Zydus Lifesciences Limited is headquartered in Ahmedabad, India, with its registered office located at 'Zydus Corporate Park'. The company operates in the life sciences sector.
Disclaimer: This story is based on company exchange filings and is for informational purposes only. Investors should evaluate risks before making decisions.
Published on: Saturday, September 26, 2026, 12:37 PM IST
RECENT STORIES
-
Zydus Lifesciences' USA Office Clears USFDA Inspection With Nil Observations -
Baanganga Gold & Diamond Sets Sights On ₹720-Crore IPO, Jewellery Firm Files Draft Papers With... -
Chitkara University Protest: Students Raise Unverified Claims Of 2 Female Students’ Suicide,... -
Sandur Manganese Incorporates Royal Sandur MedTech As Wholly Owned Subsidiary -
Gurugram Golf Course Road Stunt Video Goes Viral As Police Trace High-End Sports Car Driver Over...
